BridgeMD
New treatment option for Ascites Hepatic
Official title "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"
ClinicalTrials.gov ID: NCT07684326
What this study is testing
What is Dapagliflozin?
Dapagliflozin is an investigational medicine, being studied as a potential treatment for ascites hepatic.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to evaluate beneficial effects of using dapagliflozin in cirrhotic chronic liver disease patients. We hypnotized that the use of dapagliflozin will be associated with fewer need for large volume paracentesis hence better control of ascites, fewer need for ICU admissions, improvement of patient quality of life, better healthcare cost saving and reduced mortality rate.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult patients 18 years of age and older with a diagnosis of liver cirrhosis with any degree of ascites that led to previous or recent hospital...
You likely can't join if
- Child Pugh score ≥ 12 or MELD score \> 25.
- Previous history of hypoglycemia or has a previous history of DKA.
- Blood pressure less than 90/60 or need dose of midodrine \>15 mg/day.
- Previous history of recurrent urinary tract infections (more than 2 infections in the last 6 months) or anatomic urologic defects that predispose to...
- Pregnant or lactating female patients.
- Hypersensitivity to dapagliflozin.
See the full eligibility criteria
- Adult patients 18 years of age and older with a diagnosis of liver cirrhosis with any degree of ascites that led to previous or recent hospital admission (determined by clinical findings and imaging) will be included in...
- Child Pugh score ≥ 12 or MELD score \> 25.
- Previous history of hypoglycemia or has a previous history of DKA.
- Blood pressure less than 90/60 or need dose of midodrine \>15 mg/day.
- Previous history of recurrent urinary tract infections (more than 2 infections in the last 6 months) or anatomic urologic defects that predispose to urinary tract infection.
- Pregnant or lactating female patients.
- Hypersensitivity to dapagliflozin.
- eGFR \< 30 ml/min/1.73 m2
- Had hepatocellular carcinoma or any malignancy.
- Serum sodium level \< 125 mg/dl.
- Portal vein thrombosis.
The study team makes the final eligibility decision.
Where it's taking place
- Giza, Egypt
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Giza, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.